Magenta, the developer of a heart failure treatment device, has added an Abiomed-backed series B round to the $4m series A it raised five years ago.
Israel-based cardiac device developer Magenta Medical has closed a $15m series B round led by medical device manufacturer Abiomed.
The round included venture capital firm Pitango Venture Capital, investment firm Jafco and private investors including cardiac surgeon Jacques Seguin. It followed $4m in seed funding from Pitango Venture Capital in 2012.
Founded in 2012, Magenta is developing transcatheter devices that will help to treat acute heart failure by managing fluid retention, facilitating the safer and faster removal of liquids and…
